Navigation Links
Australia's Leading Oncology Drug Compounder Chooses RIVA System
Date:2/11/2009

WINNIPEG, Feb. 11 /PRNewswire/ - Pharmatel Fresenius Kabi Pty Ltd, one of Australia's fastest growing and most innovative pharmaceutical companies, has chosen the RIVA System (Robotic IV Automation) - a self-contained unit for filling IV syringes and bags - from Intelligent Hospital Systems (IH Systems) to consolidate its IV preparation. Pharmatel Fresenius Kabi will take delivery of its first RIVA unit in June 2009.

The RIVA System and Pharmatel Fresenius Kabi's continued investment in specialized sterile facilities are a perfect match for meeting the needs of leading-edge oncology care providers, according to Kevin McGarry, Chief Executive Officer of IH Systems. "With two Therapeutic Goods Administration (TGA) registered aseptic compounding facilities preparing tailor-made chemotherapy doses each day, Pharmatel Fresenius Kabi knows this field and knows that the RIVA System is able to meet its very high standards," says Mr. McGarry. He continues, "We are thrilled to be working with this specialist company in oncology care.

As the demands for improving patient care and safety increase, health care facilities are increasingly seeking technologically advanced, cost efficient solutions, says Jane Arnot, Vice President of Sales and Marketing with IH Systems. "One of the many attributes of the RIVA System that makes it so attractive is its flexibility to support the diverse needs of Pharmatel Fresenius Kabi's clients," shares Ms. Arnot. "The RIVA System is well suited to compounding individual patient doses of oncology drugs into a range of diverse container forms including syringes and bags, which is key to supporting convenient and flexible therapy."

Limitations in conventional clean room technology have provided challenges for manufacturers of compounded oncology products, says Iain Rosekilly, Operations Director of Pharmatel Fresenius Kabi. "Since we identified the RIVA system, Intelligent Hospital Systems has worked tirelessly with us to develop the technology to fit our business model. Their flexible and customer centred approach will ensure the successful roll out and implementation of the project." Mr. Rosekilly continues, "IV Robotics have the ability to address our market growth requirements, as well as many of the important safety aspects involved in the aseptic compounding of IV drugs, this would include increased patient safety by the elimination of dose errors, furthermore providing increased technician operator safety, RSI and other OH& S factors."

RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - is the first product developed by Winnipeg-based medical device company Intelligent Hospital Systems. For more information, please visit www.rivasystem.com.


'/>"/>
SOURCE Intelligent Hospital Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
4. Leading-edge body sensor could help produce sporting champions
5. Hospital Quality Info on Web Can Be Misleading
6. AT&T Establishes New Network Services for Leading Medical Liability Insurer
7. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
10. Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert
11. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: